This blog is part of an ongoing series, A Brave New World: Finding Life Sciences Success in Modern Markets.

The healthcare market is undergoing a fundamental shift that is reshaping how life sciences brands approach product launches, access, and early growth. Ongoing margin pressure, combined with evolving policy and reimbursement dynamics, is pushing manufacturers to rethink traditional launch and commercialization models that were built for a different environment. At the same time, the role of the patient at launch is being redefined. Patients are increasingly bypassing long-standing gatekeepers and engaging directly with brands, digital platforms, and new intermediaries that offer faster, simpler pathways to care. This dynamic creates both new opportunities and new expectations during the critical launch window.

Today’s patients expect the same transparency, convenience, and personalization at launch that they experience in retail and other digital-first industries from banking to travel.

Tech-enabled front doors, including direct-to-consumer telehealth and retail-like healthcare platforms have entered the fray by setting new standards for speed, ease, and autonomy, accelerating time to therapy initiation.

For manufacturers, this evolving backdrop demands launch models that recognize patients as active decision-makers fueled by the rise of healthcare consumerism. Successful launches are increasingly designed around patient expectations, behaviors, motivations, and lived experiences, aligning access, engagement, and support to meet patients where they are and to drive early momentum.

The Patient as Decider: A Shift in Stakeholder Influence

Historically, pharma strategy was built around a clear hierarchy. Prescribers evaluated clinical data and made treatment decisions. Payers determined access and affordability. Patients, while important, were often treated as reactive participants in the process. That hierarchy has flattened, as patients are now equipped with an expanding range of medical information. In many therapeutic areas, patients now exert influence equal to or greater than prescribers, particularly at the point of treatment initiation. This does not mean clinicians are irrelevant. Rather, their role is evolving from primary decision-maker to also being an advisor and guide.

An analysis of IQVIA’s BrandImpact^® data of over 750 primary care providers (PCPs) spanning 1.7M+ prescriptions from 2021 through 2025 indicates that more patients are entering treatment visits having already identified the product they want, driven by rising requests for obesity and respiratory products. Most notably, among top products prescribed, 27% of patient-initiated prescriptions were for diabetes products, up from 18% in 2021. Obesity and respiratory products likewise saw a jump up to 15% and 14%, respectively.

While the rise in patient requests for metabolic products are due in part to the rising popularity of glucagon-like peptide-1 (GLP-1) for weight loss, the top five therapeutic areas with the highest proportion of patient requests directly align with those with the highest direct-to-consumer (DTC) spend. This suggests that DTC messaging strategies are making an impact. Once patients are empowered with information about the treatment options available for their conditions, they are increasingly initiating treatment pathways independently, often from either the PCP’s office, or via DTC platforms. That’s not to say that excessive DTC spend alone is sufficient for success. Top performing products generally spend more on DTC at launch, but it is important to manage demand generation with return on investment to effectively manage spend.

Where consumerism has the greatest impact

While healthcare consumerism is influencing patients across therapeutic areas, its impact shows differently depending on motivation, symptom burden, and treatment journeys. Several clear patterns are emerging:

• Symptom-driven, high-motivation markets show the strongest consumer behavior. In areas where symptoms are disruptive and relief is urgent, patients often initiate care independently, research branded options, and arrive at visits with a clear treatment preference. Migraine is a clear example, with patients increasingly informed about branded Calcitonin Gene-Related Peptide (CGRP) inhibitor therapies before consultations, having compared efficacy, dosing convenience, and side-effect profiles through online research and peer communities. Telehealth platforms and nurse call lines then help translate that preference into action.
• GLP-1 therapies highlight the rise of consumer-led demand in metabolic care. Originally positioned within traditional diabetes management, GLP-1s have rapidly crossed into consumer-driven territory. Patients now actively seek specific brands based on perceived weight loss outcomes, dosing frequency, and real-world experiences shared across social media.
• Lifestyle and quality-of-life categories are increasingly shaped by patient-driven choice. Women’s health, obesity, dermatology, and sleep apnea all show patterns where symptom burden prompts direct action, and treatment choice is viewed as a personal decision tied closely to daily functioning and well-being.
• In stable chronic conditions, lifestyle fit now outweighs marginal clinical differences. In conditions like HIV, hypertension, and diabetes, once clinical control is achieved, patients increasingly prioritize lifestyle fit over marginal clinical differentiation. Convenience, routine integration, and confidence in long-term use become central to decision-making.
• Long-acting therapies heighten consumer considerations around convenience and control. Treatments administered every two or six months introduce new decision factors such as travel flexibility, appointment burden, and privacy. In these settings, patient communities play an outsized role, with shared experiences shaping expectations, normalizing trade-offs, and accelerating adoption.

Experience Data: The New Missing Ingredient in Understanding Patients

As patients behave more like consumers, the gap between clinical evidence and experiential insight becomes increasingly consequential. Clinical data remains foundational, but in certain classes, experience is becoming more influential than evidence for patient decision-making. Patients often ask different questions than regulators or payers. They want to know how a therapy feels, how disruptive it is, and how others like them have navigated side effects. When this information is absent or abstract, confidence suffers. Experience data bridges this gap. It shapes patient expectations, reduces anxiety, and supports persistence, particularly in markets where alternatives are already clinically effective. Yet many brands lack systematic ways to capture and operationalize this insight.

For brands, there are practical paths forward. Co-pay and patient support programs offer an underutilized opportunity to gather real-world experience data from opted-in users. Short, targeted surveys can capture early journey insights such as reasons for hesitation, side-effect concerns, or unmet support needs. When analyzed in near real time, this data can inform rapid adjustments to onboarding and education. Differentiation through patient-reported outcomes (PRO) should begin earlier. Collecting PROs during clinical trials and continuing through post-launch support programs enables a longitudinal understanding of benefits and trade-offs that matter to patients. This information can be used to reinforce adherence by highlighting outcomes patients value most and by preparing healthcare providers to proactively manage predictable side effects. For example, if nausea is a known early barrier, equipping prescribers to co-prescribe supportive medications and counsel patients upfront can materially reduce early drop-off.

DTC Platforms and the Consumerized Care Pathway

Patients now navigate multiple care pathways simultaneously. Traditional insurance-based care, cash-pay options, and DTC platforms coexist, and patients move between them fluidly. Retail-style DTC platforms have set a new bar for engagement as they excel at crafting clear, compelling messaging that speaks directly to patient motivations. They meet consumers where they are, reduce friction, and normalize proactive care-seeking. Pharma’s challenge is not to replicate these platforms wholesale, but to learn from them. Traditional patient services programs have historically emphasized affordability and adherence logistics. While important, these programs often lack emotional and experiential resonance. They explain what is available, not why it matters. Adopting consumer-grade communication strategies requires reframing support around patient goals rather than program features.

Where feasible, partnering with DTC platforms or integrating direct-to-patient (DTP) programs can extend reach and relevance, particularly at launch when awareness and confidence are fragile. DTP programs that allow pharma to bypass traditional models for a cohesive pharma-branded digital ecosystem have surged over the past year, driven largely by Most Favored Nation (MFN) policy. Today, 75% of top 20 pharmaceutical companies are either running a DTP program or are actively developing one, according to an IQVIA analysis.

At the same time, the number of products available by manufacturer on these platforms varies widely, ranging from a single product to as many as nine, with a median of three. This variability reflects ongoing uncertainty about which products are well suited for these platforms, and which do not make economic sense. From the patient perspective, willingness to use a DTP platform depends on a range of factors, including the condition being treated and the level of support required. Across therapeutic areas, however, there are opportunities if the right strategy is deployed based on both brand utilization and the complexity of the patient journey.

For high-utilization brands with relatively simple journeys, such as primary care chronic conditions and migraine, the greatest opportunity lies in efficiency and access at scale through tools like auto-refill, telehealth, and price transparency. As journeys become more complex, particularly in areas like diabetes, asthma, or chronic obstructive pulmonary disease COPD, and broader cardiometabolic conditions, the focus shifts to navigation and persistence enablement, using coordinated digital onboarding, hub support, and adherence programs to help patients initiate and remain on therapy. For lower-utilization or niche brands, including men’s and women’s health and mental health, DTP strategies can broaden access through awareness, cash-pay options, and pharmacy partnerships when journeys are straightforward. Highly complex specialty therapies, such as oncology, immunology, and rare diseases, benefit most from high-touch, concierge-style models that support initiation, care coordination, and long-term adherence.

Designing for a Patient at the Wheel

As patient behavior shifts, launch success increasingly depends on whether brands are designed for how decisions are actually made, not how they were assumed to be made in the past. Patients are initiating care, shaping therapy conversations, and judging experiences with a consumer mindset. For pharma executives, this requires a deliberate redesign of launch strategy, operating models, and success metrics that:

• Rebuild segmentation around motivation, not just diagnosis: Traditional segmentation anchored in demographics, clinical phenotype, or prescriber type misses what drives modern patient behavior. Two patients with the same condition can have very different urgency, privacy concerns, risk tolerance, and lifestyle constraints. Motivation-based segmentation enables more precise onboarding, messaging, and support, reducing early abandonment and increasing persistence.
• Design support models around the full experience: Many patient support programs are not designed around the full patient journey. As a result, critical moments go unmanaged, which can leave as many as 7 in 10 patients without access, as was the case for GLP-1s, for obesity. Executive teams should ensure support models address the entire journey, from symptom recognition and treatment research to early onboarding, side effect management, and the first refill decision. The highest risk of drop-off often occurs before or shortly after initiation, not months later.
• Operationalize experience insights: Patient experience data, PROs, and service interactions should inform real-time decisions, not sit in disconnected dashboards. Leading organizations integrate these signals into launch governance, using them to refine messaging, adjust support services, and equip field teams. Continuous feedback loops turn patient experience from a retrospective metric into a forward-looking growth lever.
• Build loyalty where switching is easy: In categories where alternatives are readily available, patients increasingly behave like consumers in commodity markets. Clinical differentiation alone is rarely sufficient. Loyalty is earned through emotional reassurance, predictable access, convenience, and a sense that the brand understands the patient’s life. Experience becomes the moat.
• Equip HCPs to coach, not just prescribe: Clinicians remain essential, but their role is evolving. Patients often arrive informed and opinionated. HCPs need tools that surface patient motivations quickly, help frame trade-offs in lifestyle terms, and normalize emotional concerns early. The goal is not to steer the patient, but to coach the driver. When HCPs can validate motivations and set expectations effectively, persistence and trust improve.

The Bottom Line

Patients are no longer passengers in their healthcare journey. They are driving, navigating complex choices with increasing confidence and autonomy. Policy transformation, consumerism, and innovation have converged across therapeutic areas. Companies that understand, embrace, and design for patient motivations will not only launch more effectively, but also build more resilient brands. The road ahead belongs to organizations willing to see the journey through the patient’s eyes and to design accordingly.

Please contact your IQVIA representative for more information.